This week, NHS England have been reviewing whether the chemotherapy drug Abraxane should remain on the Cancer Drugs Fund (CDF) in England. Currently, the combination of gemcitabine and Abraxane is routinely available on the NHS in Scotland and Wales but patients in England (who make up 83% of all pancreatic cancer patients) are only able to access the drug by applying to the CDF. If Abraxane is taken off the CDF, then… Read More